- Vitamins and Supplements 2014
- Allergy Relief 2014
- Perrigo recalls APAP infant suspension liquid due to the possibility of missing dose markings on the dosing syringe
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Economic analysis: Prescription-only status for PSE would drive up physician visits, healthcare costs
ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.
The new loratadine/pseudoephedrine combination formulation is the store brand equivalent to Merck Consumer's Claritin-D 12-hour extended-release tablets, which generates an approximate $111 million per year, according to Perrigo citing data provided by Wolters Kluwer.
The Loratadine-D store brand launch is the first of many new OTC products on Perrigo's launchpad this year, Perrigo chairman and CEO Joseph Papa said. "This launch is another milestone for our consumer healthcare segment, which is expected to launch many important new store brand products during this fiscal year," Papa said.